{"contentid": 488166, "importid": NaN, "name": "Myrbetriq approved in bladder condition affecting children", "introduction": "A new US indication has been approved for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO) in children ages three years and older.", "content": "<p>A new US indication has been approved for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO) in children ages three years and older.</p>\n<p>The Astellas (TYO: 4503) drugs are first-in-class to now be US Food and Drug Administration (FDA)-approved for children with NDO, a bladder dysfunction related to neurological impairment.</p>\n<p><span class=\"pullQuote\">\"Myrbetriq has been used to treat nearly 18 million adult patients worldwide with urological conditions\"</span>Treatment options for NDO have been limited or invasive, including scheduled toileting, catheterization, or surgery. If left untreated, NDO can lead to the deterioration of urinary tract function at an early age. Around 85% of children with NDO have spina bifida, a congenital spinal cord defect.</p>\n<p>Myrbetriq is also indicated for overactive bladder in adult patients.</p>\n<p>Salim Mujais, senior vice president and head, medical specialties, Astellas, said: &ldquo;With this latest approval, Astellas is bringing forward a new treatment option for children impacted by NDO, an especially vulnerable patient population with high unmet need.</p>\n<p>&ldquo;This approval marks a significant milestone for patients living with this rare but serious bladder condition that can cause unwanted accidents.</p>\n<p>&ldquo;Astellas is a long-time leader in the field of urologic health and is committed to advancing the treatment of bladder conditions that adversely impact the lives of patients. Since its initial approval nine years ago, Myrbetriq has been used to treat nearly 18 million adult patients worldwide with urological conditions.&rdquo;</p>", "date": "2021-03-26 14:05:00", "meta_title": NaN, "meta_keywords": "Myrbetriq, children, mirabegron, extended-release, bladder, approved, treat, patients, years, Astellas, affecting, condition, indication, ages, older, oral", "meta_description": "A new US indication has been approved for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspensio", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-26 14:03:30", "updated": "2021-03-26 14:30:43", "access": NaN, "url": "https://www.thepharmaletter.com/article/myrbetriq-approved-in-bladder-condition-affecting-children", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "astellas-logo-big.jpg", "image2id": "astellas-logo-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Genito-urinary", "topic_tag": "Asia Pacific, Focus On, Regulation", "geography_tag": "Japan", "company_tag": "Astellas", "drug_tag": "Myrbetriq", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-26 14:05:00"}